SCF Pharma Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
10
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof (US 11,701,337) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Feb 11, 2027The maintenance fee for Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof (US 9,101,563) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof (US 9,233,915) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,816,110 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,915 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,722,737 | Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,480,660 | Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,925,165 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,119,690 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,101,563 | Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,222,295 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,198,324 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,329,747 | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 no status recorded